Discover how the groundbreaking identification of CTBP1-DT as an immunological biomarker is revolutionizing the understanding of lipid synthesis and apoptosis resistance in kidney renal clear cell carcinoma (KIRC), offering new avenues for targeted therapies.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Identify CTBP1-DT as an immunological biomarker that promotes lipid synthesis and apoptosis resistance in KIRC.
Li et al., Gene 2024
<!– DOI: 10.1016/j.gene.2024.148403 //–>
https://doi.org/10.1016/j.gene.2024.148403
Our research delves into the role of the C-terminal binding protein-1 divergent transcript (CTBP1-DT) in kidney renal clear cell carcinoma (KIRC), a topic previously unexplored. Utilizing a variety of methods including RT-qPCR, Kaplan-Meier survival analysis, and RNA fluorescence in situ hybridization (FISH), we discovered that CTBP1-DT, a nuclear lncRNA, is significantly upregulated in KIRC and associated with improved clinical outcomes. Functional assays revealed that reducing CTBP1-DT levels hindered KIRC cell proliferation, migration, invasion, and lipid synthesis, while promoting apoptosis. Our study also ventured into the immunological aspect, examining CTBP1-DT’s influence on immune cell infiltration in KIRC through bioinformatics analysis, suggesting its potential as an immunological biomarker. Moreover, CTBP1-DT’s expression could predict the response to targeted therapies and immune checkpoint inhibitors. This research highlights CTBP1-DT’s crucial role in KIRC, offering insights into its functions in tumor biology and potential therapeutic implications.